Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:NEPH NASDAQ:SLNO NASDAQ:STRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$3.01-1.3%$5.42$2.89▼$22.20$9.21M-2.1331,361 shs37,592 shsNEPHNephros$3.78+0.5%$3.45$2.66▼$6.42$40.82M1.498,803 shs8,068 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/ASTRRStar Equity$11.16+0.1%$11.02$8.38▼$11.99$41.21M0.513,632 shs4,524 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-1.31%-24.56%-28.16%-64.50%-83.64%NEPHNephros+0.53%+4.13%+18.13%+28.14%+9.57%SLNOSoleno Therapeutics0.00%0.00%0.00%+0.44%-38.01%STRRStar Equity+0.09%-2.15%+0.72%+15.95%+466.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$3.01-1.3%$5.42$2.89▼$22.20$9.21M-2.1331,361 shs37,592 shsNEPHNephros$3.78+0.5%$3.45$2.66▼$6.42$40.82M1.498,803 shs8,068 shsSLNOSoleno Therapeutics$53.01$47.81$29.43▼$90.32$2.76B-2.221.75 million shsN/ASTRRStar Equity$11.16+0.1%$11.02$8.38▼$11.99$41.21M0.513,632 shs4,524 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys-1.31%-24.56%-28.16%-64.50%-83.64%NEPHNephros+0.53%+4.13%+18.13%+28.14%+9.57%SLNOSoleno Therapeutics0.00%0.00%0.00%+0.44%-38.01%STRRStar Equity+0.09%-2.15%+0.72%+15.95%+466.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 2.50Moderate Buy$106.673,443.74% UpsideNEPHNephros 2.33Hold$5.0032.28% UpsideSLNOSoleno Therapeutics 2.08Hold$76.6744.63% UpsideSTRRStar Equity 2.20Hold$28.00150.90% UpsideCurrent Analyst Ratings BreakdownLatest FEMY, SLNO, STRR, and NEPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026NEPHNephros Northland SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$4.007/16/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/18/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/20/2026STRRStar Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026STRRStar Equity Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/19/2026SLNOSoleno Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026SLNOSoleno Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$2.29M3.97N/AN/A$2.01 per share1.50NEPHNephros$18.79M2.18$0.13 per share29.98$0.96 per share3.94SLNOSoleno Therapeutics$285.01M9.69$0.43 per share124.10$9.51 per share5.57STRRStar Equity$172.16M0.24$0.63 per share17.60$19.12 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)NEPHNephros$1.19M$0.0754.01N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)SLNOSoleno Therapeutics$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)STRRStar Equity-$5.92M-$2.63N/A10.73N/A-4.18%-4.04%-2.40%8/6/2026 (Estimated)Latest FEMY, SLNO, STRR, and NEPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026FEMYFemasys-$1.2667N/AN/AN/A$0.73 millionN/A8/6/2026Q2 2026NEPHNephros-$0.0050N/AN/AN/A$5.05 millionN/A8/6/2026N/ASTRRStar Equity-$0.07N/AN/AN/A$56.92 millionN/A5/11/2026Q1 2026STRRStar Equity$0.05-$0.99-$1.04-$1.17$52.57 million$50.06 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 million5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.533.911.98NEPHNephrosN/A4.553.12SLNOSoleno Therapeutics0.105.625.32STRRStar Equity0.092.091.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%NEPHNephros41.10%SLNOSoleno Therapeutics97.42%STRRStar Equity3.84%Insider OwnershipCompanyInsider OwnershipFEMYFemasys7.75%NEPHNephros6.70%SLNOSoleno Therapeutics6.40%STRRStar Equity31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys303.02 million2.79 millionNot OptionableNEPHNephros3010.86 million10.13 millionNot OptionableSLNOSoleno Therapeutics3052.12 million48.78 millionOptionableSTRRStar Equity1,2003.70 million2.53 millionNot OptionableFEMY, SLNO, STRR, and NEPH HeadlinesRecent News About These CompaniesStar Equity Holdings Added to the Russell Microcap® IndexJune 29, 2026 | globenewswire.comInsider Buying: Star Equity (NASDAQ:STRR) CEO Acquires 4,766 Shares of StockJune 24, 2026 | insidertrades.comJeffrey Eberwein Acquires 4,994 Shares of Star Equity (NASDAQ:STRR) StockJune 18, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Jeffrey Eberwein Purchases 1,884 SharesJune 13, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Jeffrey Eberwein Purchases 2,849 SharesJune 10, 2026 | insidertrades.comJeffrey Eberwein Purchases 1,430 Shares of Star Equity (NASDAQ:STRR) StockJune 5, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) Director Acquires $11,600.00 in StockJune 3, 2026 | insidertrades.comStar Equity (NASDAQ:STRR) CEO Acquires $17,176.38 in StockJune 2, 2026 | insidertrades.comStar Equity Holdings, Inc. to Present at Noble Capital Markets Emerging Growth Virtual Conference on June 3-4, 2026June 1, 2026 | quiverquant.comQStar Equity Holdings to Present at the Noble Capital Markets Emerging Growth Virtual Conference on June 3-4June 1, 2026 | globenewswire.comStar Equity (NASDAQ:STRR) CEO Buys $26,906.88 in StockMay 28, 2026 | insidertrades.comInsider Stock Buying Reaches US$4.21m On Star Equity HoldingsMay 22, 2026 | finance.yahoo.comInsider Buying: Star Equity (NASDAQ:STRR) CEO Buys 4,198 Shares of StockMay 22, 2026 | insidertrades.comStar Equity Launches ATM Preferred Stock Offering ProgramMay 18, 2026 | tipranks.comStar Equity Declares Cash Dividend on Preferred StockMay 15, 2026 | tipranks.comStar Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred StockMay 15, 2026 | globenewswire.comStar Equity Holdings: Q1 Earnings SnapshotMay 11, 2026 | khou.comKStar Equity Holdings (STRR) Reports Q1 Loss, Misses Revenue EstimatesMay 11, 2026 | zacks.comStar Equity Holdings Reports Strong Q1 Revenue Growth and Achieves $2.6 Million in Merger SynergiesMay 11, 2026 | quiverquant.comQStar Equity Holdings Reports 2026 First Quarter ResultsMay 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFEMY, SLNO, STRR, and NEPH Company DescriptionsFemasys NASDAQ:FEMY$3.01 -0.04 (-1.31%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$3.02 +0.01 (+0.17%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Nephros NASDAQ:NEPH$3.78 +0.02 (+0.53%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$3.72 -0.06 (-1.59%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Soleno Therapeutics NASDAQ:SLNOSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Star Equity NASDAQ:STRR$11.16 +0.01 (+0.09%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$11.29 +0.13 (+1.16%) As of 07/17/2026 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
